



## Alzinova will attend Europe's largest Life Science conference and investor meetings this fall

Alzinova AB (publ) (FN STO: ALZ) ("Alzinova" or the "Company"), announces today that Alzinova will participate in Europe's largest Life Science conference BIO-Europe. The conference is a gathering place for partnering meetings where the Company will present the vaccine candidate ALZ-101 and the antibody ALZ-201 to potential partners. Furthermore, the Company will present at Redeye's theme day on neurology.

### **BIO-Europe, November 6-8**

BIO-Europe, the pharmaceutical industry's largest partnering meeting in Europe, is held this year in Munich on November 6-8. The event typically gathers tens of thousands of delegates from around the world, who meet to discuss licensing deals and research collaborations. Alzinova's CEO, Kristina Torfgård and Business Development Director, Sebastian Hansson will meet discussion partners from their global network in the pharmaceutical industry and establish new contacts with a focus on presenting and marketing the Company's pharmaceutical projects. Read more here: <https://informaconnect.com/bioeurope/>

### **Redeye Theme: Neurology October 11**

For the sixth year, Redeye is organizing an event focusing on drug development in neurology and brain diseases. The event starts with an introduction to the topic and then continues with company presentations.

Alzinova's CEO Kristina Torfgård will present the company and talk about the latest progress at 11.05 am. The event, which takes place on October 11, will be broadcast live and Alzinova's presentation can be seen on Redeye's website live via: <https://www.redeye.se/events/910705/redeye-neurology-seminar-cns>. The presentation will also be available on Alzinova's website afterwards via the following link: <https://www.alzinova.com/investors/presentations/>.

Alzinova plans to participate in additional investor meetings during the fall and will announce when new events have been scheduled.

### **For more information, please contact:**

Kristina Torfgård, CEO  
Tel. +46 708 46 79 75  
E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*



### **About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

### **Attachments**

**Alzinova will attend Europe's largest Life Science conference and investor meetings this fall**